ALCAM and breast carcinoma: By investigating the relationship between CD166 and BI-RADS, we hope to find out whether CD166 can be used as a valuable adjunct biomarker to improve the predictive capacity of the BI-RADS classification, ultimately assisting in early diagnosis, risk stratification, and personalized treatment approaches for breast cancer patients.